MX2021000698A - Peptidos anti-inflamatorios orales para tratar la epilepsia, convulsiones y trastornos del snc. - Google Patents

Peptidos anti-inflamatorios orales para tratar la epilepsia, convulsiones y trastornos del snc.

Info

Publication number
MX2021000698A
MX2021000698A MX2021000698A MX2021000698A MX2021000698A MX 2021000698 A MX2021000698 A MX 2021000698A MX 2021000698 A MX2021000698 A MX 2021000698A MX 2021000698 A MX2021000698 A MX 2021000698A MX 2021000698 A MX2021000698 A MX 2021000698A
Authority
MX
Mexico
Prior art keywords
peptide
thr
ser
asn
seizures
Prior art date
Application number
MX2021000698A
Other languages
English (en)
Inventor
Michael Ruff
Original Assignee
Creative Bio Peptides Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Bio Peptides Inc filed Critical Creative Bio Peptides Inc
Publication of MX2021000698A publication Critical patent/MX2021000698A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para tratar convulsiones, epilepsia o pérdida de la función cerebral en un individuo que comprende las etapas de preparar una composición compuesta por un péptido de todos los aminoácidos D y un vehículo farmacéuticamente aceptable. El péptido D tiene la estructura general: A-B-C-D-E en donde A es Ser, Thr, Asn, Glu, Ile B es Ser, Thr, Asp, Asn, C es Thr, Ser, Asn, Arg, Lys, Trp, D es Tyr y E es Thr, Ser, Arg, Gly Y en donde todos los aminoácidos en el péptido D tienen la configuración estereoisomérica D y dicha composición de péptido se administra en una dosis terapéuticamente efectiva en donde dicha composición actúa para suprimir la inflamación subyacente a la pérdida de la función cerebral. El péptido D puede esterificarse, glicosilarse o amidarse en E para mejorar la distribución tisular promoviendo la salida de la circulación y la penetración en el cerebro.
MX2021000698A 2017-07-18 2019-07-09 Peptidos anti-inflamatorios orales para tratar la epilepsia, convulsiones y trastornos del snc. MX2021000698A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533854P 2017-07-18 2017-07-18
US16/038,144 US20190022166A1 (en) 2017-07-18 2018-07-17 Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
PCT/US2019/040977 WO2020018315A2 (en) 2017-07-18 2019-07-09 Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders

Publications (1)

Publication Number Publication Date
MX2021000698A true MX2021000698A (es) 2021-05-31

Family

ID=65014339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000698A MX2021000698A (es) 2017-07-18 2019-07-09 Peptidos anti-inflamatorios orales para tratar la epilepsia, convulsiones y trastornos del snc.

Country Status (7)

Country Link
US (1) US20190022166A1 (es)
EP (1) EP3823658A2 (es)
JP (1) JP2021530570A (es)
CN (1) CN112703008A (es)
CA (1) CA3106817A1 (es)
MX (1) MX2021000698A (es)
WO (1) WO2020018315A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624944B2 (en) * 2017-06-19 2020-04-21 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH)
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
EP4039264A1 (en) * 2021-02-08 2022-08-10 Creative Bio-Peptides Inc. Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
CA3218938A1 (en) * 2021-05-20 2022-11-24 Michael Ruff Compositions and methods for treating neuropathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104558200B (zh) * 2004-09-02 2021-11-16 康石医药科技（上海）有限公司 改进的apo e类似物及其使用方法
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
EP2168983A1 (fr) * 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
US8871259B2 (en) * 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US10501494B2 (en) * 2013-04-26 2019-12-10 Creative Bio-Peptides Uses of peptides to treat brain injury and disease

Also Published As

Publication number Publication date
US20190022166A1 (en) 2019-01-24
CN112703008A (zh) 2021-04-23
WO2020018315A3 (en) 2020-02-13
CA3106817A1 (en) 2020-01-23
EP3823658A2 (en) 2021-05-26
JP2021530570A (ja) 2021-11-11
WO2020018315A2 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2021000698A (es) Peptidos anti-inflamatorios orales para tratar la epilepsia, convulsiones y trastornos del snc.
PH12018502634A1 (en) Topical compositions of apremilast
PH12018500162A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
IL262805B2 (en) CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death
NZ601868A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
EP3533877A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
WO2012012600A3 (en) Peptide compounds for regulating the complement system
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
WO2022076556A3 (en) Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
MX2021010568A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
RU2017128296A (ru) Композиция для лечения бесплодия
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
NZ736642A (en) Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
WO2016130518A3 (en) Methods and compositions for treating muscle disease and disorders
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides